Clinical trial NCT01600807: OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas
Official title: Phase I/II Trial of OSI-906 in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Ductal Adenocarcinoma of the Pancreas
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
PHASE2
Conditions: Pancreatic Cancer, Metastatic
Keywords: Metastatic
Pancreas
Cancer
Adenocarcinoma
Lead sponsor: Dana-Farber Cancer Institute
Sponsor class: OTHER
First posted: 2012-05-17
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: OSI-906 is a new drug that may stop cancer cells from growing abnormally. This drug has been used in other research studies and information from those suggests that OSI-906 may help block cell receptors involved in tumor growth.

Gemcitabine and erlotinib are used as standard treatment for pancreatic cancer. In this research study, the investigators are looking for the highest dose of OSI-906 that can be given safely in combination with gemcitabine and erlotinib. This dose will then be given together with gemcitabine and erlotinib to a further group of patients with pancreatic cancer.

Detailed description: This study will be conducted in two parts: a phase I study and a phase II study. In both instances, a treatment cycle is 28 days (4 weeks). Subjects will take OSI-906 by mouth, twice a day, every day. Subjects will receive gemcitabine through an IV in clinic over 30 minutes on days 1, 8 and 15 of each 28-day cycle. Subjects will take erlotinib by mouth, once a day, every day.

At every visit subjects will have a physical exam and blood tests. An EKG will be done on days 1, 8 and 15 of cycle 1 and on day 1 of all subsequent cycles. A CT scan will be done every 2 cycles (8 weeks).

Subjects will complete a daily drug diary and perform glucose monitoring (finger stick) once daily at home.

Eligibility criteria: Inclusion Criteria:

* Metastatic pancreatic ductal adenocarcinoma
* Measurable disease
* Life expectancy \> 12 weeks
* Normal organ and marrow function
* Fasting blood glucose \</= 150 mg/dL
* Able to swallow pills

Exclusion Criteria:

* Prior chemotherapy or radiotherapy for treatment of pancreatic cancer
* Receiving any other experimental agent
* Known brain metastases
* History of allergic reaction attributed to compounds of similar chemical or biologic composition to gemcitabine, erlotinib, or OSI-906
* Impairment of gastrointestinal function or gastrointestinal disease (e.g., ulcerative disease, uncontrolled nausea, vomiting, or diarrhea)
* Use of enzyme-inducing anti-epileptic drugs
* Diabetes mellitus which requires the use of exogenous insulin for glucose control
* Major surgery within 4 weeks of the start of study treatment
* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Use of strong or moderate CYP1A2 inhibitors/inducers
* Pregnant or breast feeding
* History of a different malignancy unless disease-free for at least 3 years
* HIV positive

Primary outcomes:
measure: Number of patients with adverse events as a measure of safety and tolerability
timeFrame: 1 years
measure: Survival among patients receiving gemcitabine + erlotinib versus gemcitabine + erlotinib + OSI-906
timeFrame: 2 years
Secondary outcomes:
measure: Progression-free survival among patients receiving gemcitabine + erlotinib vs. gemcitabine + erlotinib + OSI-906
timeFrame: 2 years
measure: Tumor response rate among patients receiving gemcitabine + erlotinib versus gemcitabine + erlotinib + OSI-906
timeFrame: 2 years
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
Study officials:
affiliation: Dana-Farber Cancer Institute
name: Brian Wolpin, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References: